查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153427

2026-2034年全球肺癌診斷檢測市場規模、佔有率、趨勢和成長分析報告

Global Lung Cancer Diagnostic Tests Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 262 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球肺癌診斷檢測市場預計將從2025年的160億美元成長至2034年的324.4億美元，2026年至2034年的複合年成長率（CAGR）為8.17%。隨著醫療系統日益重視肺癌的早期檢測、準確的疾病分類和及時的治療計劃，該市場正在不斷擴張。肺癌診斷檢測包括影像檢查、組織切片檢查、分子檢測以及其他用於識別和表徵可疑肺部病變的方法。人們對肺癌風險因素的認知不斷提高、診斷服務的普及以及醫學影像技術的進步都推動了市場需求。在已實施篩檢計畫的地區，針對特定高風險族群的低劑量CT篩檢也至關重要。這些發展趨勢促使醫療機構改善診斷流程，並更好地將篩檢與專科診療結合。

市場成長主要得益於分子診斷技術的進步、影像技術的廣泛應用以及對個人化癌症治療日益成長的需求。診斷實驗室正在不斷提升其識別基因突變和生物標記的能力，從而指導標靶治療決策。儘管人工智慧（AI）驅動的影像工具正在開發中，以輔助影像解讀和識別可疑觀察，但臨床檢驗仍然至關重要。微創切片檢查技術和分子檢測技術的進步也幫助臨床醫生獲得更多關於腫瘤的資訊。此外，對癌症研究的投入以及呼吸腫瘤專科服務的普及也促進了診斷能力的提升。

肺癌市場的未來前景將受到早期檢測、液態生物檢體、分子譜分析和人工智慧成像技術進步的影響。雖然基於血液檢測的方法可能有助於研究人員開發創傷性較小的疾病相關訊號識別方法，但其臨床應用取決於相關證據和監管部門的批准。影像學、病理學和基因組學數據的整合有助於醫療專業人員做出更準確的診斷和治療決策。然而，假陽性觀察、診斷成本、篩檢機會不均以及確診檢測的需求仍然是重大挑戰。持續的臨床研究和診斷基礎設施的改進對於支持可靠及時的肺癌診斷至關重要。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球肺癌診斷檢測市場：依癌症類型分類

  • 市場分析、洞察與預測
  • 非小細胞肺癌（NSCLC）
  • 小細胞肺癌（SCLC）

第5章 全球肺癌診斷測試市場：依測試類型分類

  • 市場分析、洞察與預測
  • 影像檢查
  • 痰液細胞學
  • 切片檢查
  • 分子檢測
  • 其他測試

第6章 全球肺癌診斷檢測市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 專科診所
  • 其他設施

第7章 全球肺癌診斷檢測市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Roche
    • Abbott
    • Thermo Fisher Scientific
    • QIAGEN
    • Foundation Medicine
    • Guardant Health
    • Exact Sciences
    • Biodesix
    • Veracyte
    • NeoGenomics
    • Burning Rock Biotech
    • Amoy Diagnostics
    • Bio-Rad Laboratories
    • Agilent Technologies
    • Illumina
    • Natera
    • Geneseeq
    • Singlera Genomics
    • Guardant
    • Personalis
簡介目錄
Product Code: VMR11218500

The global lung cancer diagnostic tests market size is expected to reach USD 32.44 Billion in 2034 from USD 16.00 Billion in 2025, growing at a CAGR of 8.17% during 2026-2034.This market is expanding as healthcare systems increasingly emphasize early lung cancer detection, accurate disease classification, and timely treatment planning. Diagnostic testing for lung cancer includes imaging procedures, tissue biopsies, molecular testing, and other methods used to identify and characterize suspicious lung lesions. Growing awareness of lung cancer risk factors, expanding access to diagnostic services, and improvements in medical imaging are supporting demand. Low-dose computed tomography screening is also important for eligible high-risk populations in settings where screening programs are available. These developments are encouraging healthcare providers to strengthen diagnostic pathways and improve coordination between screening and specialist care.

Market growth is driven by advances in molecular diagnostics, increasing use of imaging technologies, and growing demand for personalized oncology. Diagnostic laboratories are expanding their capabilities to identify genetic alterations and biomarkers that can help guide targeted treatment decisions. Artificial intelligence-assisted imaging tools are being developed to support image interpretation and identify suspicious findings, although clinical validation remains important. Improvements in minimally invasive biopsy techniques and molecular testing are also helping clinicians obtain information about tumors. In addition, investments in cancer research and expanded access to specialized respiratory and oncology services are supporting the development of diagnostic capabilities.

The future prospects of this market will be shaped by advances in early detection, liquid biopsy, molecular profiling, and AI-assisted imaging. Blood-based testing approaches may help researchers develop less invasive methods for identifying disease-related signals, although their clinical roles depend on supporting evidence and regulatory approval. Greater integration of imaging, pathology, and genomic data could help healthcare professionals make more informed diagnostic and treatment decisions. However, false-positive findings, diagnostic costs, unequal access to screening, and the need for confirmatory testing remain important challenges. Continued clinical research and improvements in diagnostic infrastructure will be essential for supporting reliable and timely lung cancer diagnosis.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Cancer Type

  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)

By Test Type

  • Imaging Tests
  • Sputum Cytology
  • Biopsy
  • Molecular Tests
  • Other Tests

By End User

  • Hospitals
  • Specialty Clinics
  • Other Facilities

COMPANIES PROFILED

  • Roche, Abbott, Thermo Fisher Scientific, QIAGEN, Foundation Medicine, Guardant Health, Exact Sciences, Biodesix, Veracyte, NeoGenomics, Burning Rock Biotech, Amoy Diagnostics, Bio-Rad Laboratories, Agilent Technologies, Illumina, Natera, Geneseeq, Singlera Genomics, Guardant, Personalis

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL LUNG CANCER DIAGNOSTIC TESTS MARKET: BY CANCER TYPE 2022-2034 (USD MN and Units)

  • 4.1. Market Analysis, Insights and Forecast Cancer Type
  • 4.2. Non-Small Cell Lung Cancer (NSCLC) Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
  • 4.3. Small Cell Lung Cancer (SCLC) Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 5. GLOBAL LUNG CANCER DIAGNOSTIC TESTS MARKET: BY TEST TYPE 2022-2034 (USD MN and Units)

  • 5.1. Market Analysis, Insights and Forecast Test Type
  • 5.2. Imaging Tests Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
  • 5.3. Sputum Cytology Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
  • 5.4. Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
  • 5.5. Molecular Tests Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
  • 5.6. Other Tests Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 6. GLOBAL LUNG CANCER DIAGNOSTIC TESTS MARKET: BY END USER 2022-2034 (USD MN and Units)

  • 6.1. Market Analysis, Insights and Forecast End User
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
  • 6.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
  • 6.4. Other Facilities Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 7. GLOBAL LUNG CANCER DIAGNOSTIC TESTS MARKET: BY REGION 2022-2034 (USD MN and Units)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
    • 7.2.1 By Cancer Type
    • 7.2.2 By Test Type
    • 7.2.3 By End User
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
    • 7.3.1 By Cancer Type
    • 7.3.2 By Test Type
    • 7.3.3 By End User
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Spain
    • 7.3.9 Russia
    • 7.3.10 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
    • 7.4.1 By Cancer Type
    • 7.4.2 By Test Type
    • 7.4.3 By End User
    • 7.4.4 China
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 India
    • 7.4.8 Australia
    • 7.4.9 South East Asia
    • 7.4.10 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
    • 7.5.1 By Cancer Type
    • 7.5.2 By Test Type
    • 7.5.3 By End User
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
    • 7.6.1 By Cancer Type
    • 7.6.2 By Test Type
    • 7.6.3 By End User
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL LUNG CANCER DIAGNOSTIC TESTS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Roche
    • 9.2.2 Abbott
    • 9.2.3 Thermo Fisher Scientific
    • 9.2.4 QIAGEN
    • 9.2.5 Foundation Medicine
    • 9.2.6 Guardant Health
    • 9.2.7 Exact Sciences
    • 9.2.8 Biodesix
    • 9.2.9 Veracyte
    • 9.2.10 NeoGenomics
    • 9.2.11 Burning Rock Biotech
    • 9.2.12 Amoy Diagnostics
    • 9.2.13 Bio-Rad Laboratories
    • 9.2.14 Agilent Technologies
    • 9.2.15 Illumina
    • 9.2.16 Natera
    • 9.2.17 Geneseeq
    • 9.2.18 Singlera Genomics
    • 9.2.19 Guardant
    • 9.2.20 Personalis